



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
Telephone: +1-925-399-1568  
E-mail: office@baishideng.com  
<https://www.wjgnet.com>

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 88057

**Title:** Elucidating the molecular basis of ATP-induced cell death in breast cancer:  
Construction a robust prognostic model

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02686084

**Position:** Editorial Board

**Academic degree:** MSc

**Professional title:** Research Scientist

**Reviewer's Country/Territory:** Mexico

**Author's Country/Territory:** Malaysia

**Manuscript submission date:** 2023-09-08

**Reviewer chosen by:** Yu-Lu Chen

**Reviewer accepted review:** 2023-11-16 23:40

**Reviewer performed review:** 2023-11-24 18:56

**Review time:** 7 Days and 19 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



# Baishideng Publishing Group

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** office@baishideng.com  
<https://www.wjgnet.com>

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

The text has spelling and editorial errors that are noted in the manuscript. You are requested to review and address the observations



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 88057

**Title:** Elucidating the molecular basis of ATP-induced cell death in breast cancer:  
Construction a robust prognostic model

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02684216

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Full Professor

**Reviewer's Country/Territory:** Iran

**Author's Country/Territory:** Malaysia

**Manuscript submission date:** 2023-09-08

**Reviewer chosen by:** Yu-Lu Chen

**Reviewer accepted review:** 2023-11-16 18:56

**Reviewer performed review:** 2023-11-29 03:07

**Review time:** 12 Days and 8 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

-The authors have aimed to explicate" the Molecular Basis of ATP-Induced Cell Death in Breast Cancer: Construction and Validation of a Robust Prognostic Model" through literature review. -By constructing "a miRNA prognostic model and mirroring the gene-based prognostic model, as autonomous prognostic factors "& - Aiming grouping analysis. -"MATERIALS AND METHODS: Literature search of AICD core genes" -Analysis of data is, absolutely, performed based on grouping. In fact personalized insight is required to be considered, i.e., at single cell level. - "Exploring the entire dataset's risk score distribution and expression heat map." also reflect the global insight. It is stated that: - :"The findings of this study show that AICD could be a potential target for breast cancer detection and therapeutic intervention, opening up a new research channel and perspective for breast cancer diagnostic and treatment. This discovery holds promise in providing valuable insights for precision treatment and accurate prognosis assessment of breast cancer." - The required analytical insight includes single cell assay of the end point of the road , i.e., Protein expression at single cell level by very high enumeration. - In brief: Single insight of cancer cells in each patient is required to be, separately, assayed , analyzed and discussed. - There is no destination for group-analysis. Cancer is the single cell based territory. - The key aims include: Considering the functional insight, and at single cell level. Otherwise, the road map will not provide the translatable, personalized insight.